Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Groen

Showing results (421-430 of 456) with videos related to

Pageof 46
Sort By:
Cell Reports|January 11, 2016
Non-canonical PRC1.1 Targets Active Genes Independent of H3K27me3 and Is Essential for LeukemogenesisVincent van den Boom, Henny Maat, Marjan Geugien, et al.
JAMA Oncology|August 28, 2025
Iodine Seed-Marking Protocol for Response-Guided Axillary Treatment After Systemic Therapy for Node-Positive Breast CancerAnnemiek K E van Hemert, Ariane A van Loevezijn, Marie-Sophie P D Baas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 16, 2014
Preclinical Evidence for the Therapeutic Potential of CD38-Targeted Immuno-Chemotherapy in Multiple Myeloma Patients Refractory to Lenalidomide and BortezomibInger S Nijhof, Richard W J Groen, Willy A Noort, et al.
Haematologica|September 8, 2018
CD38 as a therapeutic target for adult acute myeloid leukemia and T-cell acute lymphoblastic leukemiaJyoti Naik, Maria Themeli, Regina de Jong-Korlaar, et al.
The American Journal of Surgical Pathology|June 18, 2019
Discordant Marker Expression Between Invasive Breast Carcinoma and Corresponding Synchronous and Preceding DCISLindy L Visser, Lotte E Elshof, Koen Van de Vijver, et al.
Hemasphere|September 14, 2020
Complete Tumor Regression by Liposomal Bortezomib in a Humanized Mouse Model of Multiple MyelomaAnil K Deshantri, Marcel H A M Fens, Ruud W J Ruiter, et al.
Haematologica|February 10, 2016
Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myelomaEsther Drent, Richard W J Groen, Willy A Noort, et al.
Haematologica|May 7, 2016
Sepantronium bromide (YM155) improves daratumumab-mediated cellular lysis of multiple myeloma cells by abrogation of bone marrow stromal cell-induced resistanceSanne J de Haart, Lisa Holthof, Willy A Noort, et al.
Haematologica|May 25, 2019
Preclinical evidence for an effective therapeutic activity of FL118, a novel survivin inhibitor, in patients with relapsed/refractory multiple myelomaLisa C Holthof, Hilma J van der Horst, Susan E van Hal-van Veen, et al.
Hemasphere|November 15, 2024
Preclinical evaluation of the CD38-targeting engineered toxin body MT-0169 against multiple myelomaWassilis S C Bruins, Rosa Rentenaar, John Newcomb, et al.
Pageof 46

Showing results (421-430 of 456) with videos related to

Sort By:
Pageof 46
Cell Reports|January 11, 2016
Non-canonical PRC1.1 Targets Active Genes Independent of H3K27me3 and Is Essential for LeukemogenesisVincent van den Boom, Henny Maat, Marjan Geugien, et al.
JAMA Oncology|August 28, 2025
Iodine Seed-Marking Protocol for Response-Guided Axillary Treatment After Systemic Therapy for Node-Positive Breast CancerAnnemiek K E van Hemert, Ariane A van Loevezijn, Marie-Sophie P D Baas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 16, 2014
Preclinical Evidence for the Therapeutic Potential of CD38-Targeted Immuno-Chemotherapy in Multiple Myeloma Patients Refractory to Lenalidomide and BortezomibInger S Nijhof, Richard W J Groen, Willy A Noort, et al.
Haematologica|September 8, 2018
CD38 as a therapeutic target for adult acute myeloid leukemia and T-cell acute lymphoblastic leukemiaJyoti Naik, Maria Themeli, Regina de Jong-Korlaar, et al.
The American Journal of Surgical Pathology|June 18, 2019
Discordant Marker Expression Between Invasive Breast Carcinoma and Corresponding Synchronous and Preceding DCISLindy L Visser, Lotte E Elshof, Koen Van de Vijver, et al.
Hemasphere|September 14, 2020
Complete Tumor Regression by Liposomal Bortezomib in a Humanized Mouse Model of Multiple MyelomaAnil K Deshantri, Marcel H A M Fens, Ruud W J Ruiter, et al.
Haematologica|February 10, 2016
Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myelomaEsther Drent, Richard W J Groen, Willy A Noort, et al.
Haematologica|May 7, 2016
Sepantronium bromide (YM155) improves daratumumab-mediated cellular lysis of multiple myeloma cells by abrogation of bone marrow stromal cell-induced resistanceSanne J de Haart, Lisa Holthof, Willy A Noort, et al.
Haematologica|May 25, 2019
Preclinical evidence for an effective therapeutic activity of FL118, a novel survivin inhibitor, in patients with relapsed/refractory multiple myelomaLisa C Holthof, Hilma J van der Horst, Susan E van Hal-van Veen, et al.
Hemasphere|November 15, 2024
Preclinical evaluation of the CD38-targeting engineered toxin body MT-0169 against multiple myelomaWassilis S C Bruins, Rosa Rentenaar, John Newcomb, et al.
Pageof 46